A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics

Miriam Meyer, Andrea Mahr, Joanna Brewer, Volker Daniel, Justine Dell‘Aringa, Tony Goldstone, Sarah Hersey, Ian Johnston, Pamela Larson, Michael Loveridge, Gavin MacBeath, Mark Moyer, Dirk Nagorsen, Sophie Papa, Leanne Peiser, Koustubh Ranade, Ruben Rizzi, Axel Roers, Dolores Schendel, Pallavur SivakumarEric Tran, Özlem Türeci, Luise Weigand, Anders Wennborg, Dennis Williams, Cassian Yee, Cedrik M. Britten

Research output: Contribution to journalComment/debatepeer-review

Abstract

Current regulation of T cell receptor (TCR)-based therapeutics may require repeated testing of patients for specific HLA alleles as well as companion diagnostics development, despite the invariant nature of the HLA genotype and availability of robust clinical HLA tests. This increases the burden on patients and the organizations developing these products. We propose regulatory flexibility to facilitate the development of and access to TCR-based therapeutics.

Original languageEnglish (US)
Pages (from-to)1-2
Number of pages2
JournalNature Reviews Drug Discovery
Volume23
Issue number1
DOIs
StatePublished - Jan 2024

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics'. Together they form a unique fingerprint.

Cite this